大型尿毒症毒素:终末期肾病中未解决的问题
本文综述了终末期肾病(ESKD)维持性血液透析患者中滞留的18种分子量在15至60 kDa的尿毒症毒素,这些毒素与炎症和/或心血管疾病相关。现有高通量膜清除有限,新型中截留量透析膜可改善清除,但需可靠临床试验评估其能否改善结局。
要点
- ESKD透析患者炎症和心血管疾病负担高,部分由尿毒症溶质潴留驱动。
- 高通量膜对>15 kDa溶质清除有限,中截留量膜可清除高达50 kDa的中大分子。
- 改善大型尿毒症毒素清除能否改善结局尚需可靠临床试验验证。
核心结论
- 改善大型尿毒症毒素清除有望通过减轻心血管疾病负担来改善透析患者结局,但需可靠临床试验评估。
研究设计与样本
- 综述,讨论了18种分子量在15至60 kDa之间、在ESKD中滞留且与炎症和/或心血管疾病相关的尿毒症毒素。
主要发现
- 现有高通量膜透析对>15 kDa溶质清除有限。
- 新型中截留量透析膜孔大于高通量膜,可改善高达50 kDa中大分子的清除。
- 滞留的18种毒素包括炎症蛋白、细胞因子、脂肪因子和其他信号蛋白。
临床怎么用
- 关注中截留量透析膜在清除大型尿毒症毒素方面的潜在应用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis are subject to a high burden of inflammation and cardiovascular disease, driven at least in part by retention of uremic solutes. Existing dialysis technologies using high-flux membranes offer limited clearance of solutes >15 kDa. New approaches to improve the removal of large uremic toxins include the novel medium cut-off dialysis membranes with pores larger than those in high-flux membranes. These new membranes provide the potential to improve the clearance of large middle molecules up to 50 kDa. In this review, we discuss 18 uremic toxins with molecular weights between 15 and 60 kDa that are retained in ESKD, for which there is evidence of a link to inflammation and/or cardiovascular disease. These include inflammatory proteins, cytokines, adipokines and other signaling proteins. Improved clearance of this group of difficult to remove molecules has the potential to lead to improved outcomes in dialysis patients by reducing the burden of cardiovascular disease, which now needs to be assessed in robust clinical trials.
引用
- Wolley MJ, Hutchison CA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant. 2018. PMID: 30281131. doi:10.1093/ndt/gfy179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。